comparemela.com
Home
Live Updates
4D Molecular Therapeutics 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast - 4D Molecular Therapeutics (NASDAQ:FDMT) : comparemela.com
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast - 4D Molecular Therapeutics (NASDAQ:FDMT)
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.
Related Keywords
,
Kostas Biliouris ,
Regeneron Pharmaceutical Inc ,
Molecular Therapeutic ,
Age Related Macular ,
Molecular Therapeutics ,
comparemela.com © 2020. All Rights Reserved.